2023
Aiming for the cure in myeloma: Putting our best foot forward
Bar N, Firestone R, Usmani S. Aiming for the cure in myeloma: Putting our best foot forward. Blood Reviews 2023, 62: 101116. PMID: 37596172, DOI: 10.1016/j.blre.2023.101116.Peer-Reviewed Original ResearchConceptsMultiple myelomaMinimal residual disease negativityDeeper response ratesResponse-adapted strategyDuration of therapyPowerful prognostic factorSignificant inter-patient variabilityNovel clinical trialsInter-patient variabilityRegimen compositionFrontline therapyUpfront therapyPrognostic factorsMyeloma patientsMyeloma treatmentClinical trialsTreatment strategiesCurrent relevant literatureTreatment approachesResponse rateDisease riskTherapyMyelomaUse of transplantsCurrent standard
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma